This current wave of biotech investment aligns with a broader investor thesis that views the sector as a ripe area for growth.
The biotech industry is witnessing a revival in the early months of 2024 with a series of IPOs worth around $100 million or more and startup financings. This uptick, along with the recovery of biotech’s flagship stock funds and a surge in dealmaking, has sparked optimism about the industry's health.
The recent success stories include companies like CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma, which not only raised more funds than anticipated but also saw their stock prices increase post-IPO. Biotech venture capital has pulled in approximately $15 billion annually in the last two years.
Invivo Partners, a Barcelona-based venture capital firm, is close to securing a new fund of €100 million ($109 million), with a potential to extend up to €120 million, marking its third fund since inception. The firm has conducted notable acquisitions like Sanifit Therapeutics by Vifor Pharma for €205 million and Versantis by Genfit for about €43 million.
However, the sustainability of this IPO resurgence remains uncertain. Following a brisk period of activity in late January and early February, no new IPO plans have been announced.
Observers are cautiously watching whether this initial burst will translate into sustained growth for the sector or if it represents a temporary spike in a typically volatile market landscape.
The IPO slowdown since late 2021 has had a cascading effect on venture funding for biotech startups, making it more challenging to raise funds at desirable valuations.
The focus on late-stage, de-risked investments raises questions about the financing landscape for early-stage biotech innovators and whether a shift in investor sentiment could broaden the pool of IPO candidates.
This current wave of investment aligns with a broader investor thesis that views biotech as a ripe area for growth, driven by technological advancements and an increasing demand for healthcare innovation.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/the-biotech-resurgence"
},
"headline": "The Biotech Resurgence",
"description": "This current wave of biotech investment aligns with a broader investor thesis that views the sector as a ripe area for growth.",
"image": "",
"author": {
"@type": "Organization",
"name": "The Money Game",
"url": "https://www.themoney.game"
},
"publisher": {
"@type": "Organization",
"name": "",
"logo": {
"@type": "ImageObject",
"url": ""
}
},
"datePublished": "2024-03-07"
}
</script>
Actions
Pages
Subscribe for newsletter
Stories
ATCO, an energy and utilities conglomerate, has acquired Suncor Energy Inc.'s wind and solar assets across Alberta and Ontario and forged a renewable energy deal with Microsoft. This partnership highlights Microsoft’s decarbonization goals and the strength of ATCO’s green power infrastructure.
ATCO and Microsoft working together could catalyze further investments from big tech and can accelerate the expansion of alternative energy sources.
"Today represents two big steps forward on our commitment to become a leader in decarbonization," said Bob Myles, Executive Vice President, Corporate Development, ATCO.
As ATCO expands its renewable energy footprint, anticipate a surge in similar partnerships between energy and tech firms. This trend not only paves the way for a decarbonized future but also sets a new standard in corporate responsibility.
Contrary to the belief that traditional energy companies might lag in renewable adoption, ATCO's move proves otherwise, signaling a shift in industry priorities.
Story
Innovators
Scroll
Open
Close